Lipid lowering to delay the progression of coronary artery disease

Heart

Volumn 89, Issue 4, 2003, Pages 451-458

  Feher, Michael D ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ANGINA PECTORIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DYSPEPSIA; ERECTILE DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIVER TOXICITY; MORTALITY; MYALGIA; MYOPATHY; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SLEEP DISORDER; TREATMENT PLANNING;

EID: 0037379877     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.4.451     Document Type: Review

References (16)

1. Roussouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;323:1112-19.
2. Pekannen J, Linn S, Heiss G, et al. Ten year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease. N Engl J Med 1990;322:1700-7.
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26. Seminal paper on the pathogenesis of atherosclerosis.
4. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):S1-S29.
5. Department of Health. National service framework for coronary heart disease. London: HMSO, 2000.
6. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the second joint task force of European and other societies on coronary prevention. Atherosclerosis 1998;140:199-270.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
8. Fodor G, Frolich JJ, Genest Jr FFG, et al for the Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management and treatment of dyslipidemia. Can Med Assoc J 2000;162:1441-7.
9. Sacks FM, Tonkin A, Shepherd J, et al for the Prospective Pravastatin Pooling Project Investigators Group. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the prospective pravastatin pooling project. Circulation 2000;102:1893-900. Pooled data from several pravastatin trials with increased number of subjects increasing the power to analyse subgroups. Important findings of reduced CHD and stroke with lipid lowering.
10. Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002;287:3087-95. Results on 12 365 patients treated with statins within seven days of an acute coronary syndrome (that is, early statin initiation) showed no improvement in clinical outcome at one year.
11. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;20:139-43. Review of epidemiology and clinical role of HDL in the prevention of CHD.
12. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with law LDL-cholesterol. Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002;105:1424-8. Results of pooled trial data indicating the therapeutic potential for improving HDL and triglycerides in patients with CHD but a low LDL. Statin treatment reduced the clinical event rate to that seen in a non-diabetic group.
13. Durrington PN, Illingworth DR. Lipid-lowering drug therapy: more knowledge leads to more problems for composers of guidelines. Curr Opin Lipidol 2000;11:345-9. Review of the greater CHD benefits of triglyceride lowering trials compared to cholesterol lowering trials.
14. Feher MD, Foxton J, Banks D, et al. Long-term safety of statin-fibrate combination therapy in the treatment of hypercholesterolaemia in patients with coronary artery disease. Br Heart J 1995;74:14-17. One to three year follow up of statin-fibrate combination. Compliant patients without other treatment confounders may explain the enhanced cholesterol lowering and lack of clinical hazard with this drug combination.
15. Shepherd J. The statin era: in search of the ideal lipid regulating agent. Heart 2001;85:259.
16. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-73. Review of the treatment benefits of cholesterol lowering in the diet and drug trials over time and the impact at different ages.